MiMedx Group, Inc.
NASDAQ:MDXGBiotechnology
+$0.08 today
- Market cap
- $464.04M
- Beta
- 1.46
- P/E (TTM)
- 17.8
- EPS (TTM)
- $0.21
Volume 1.51M
Average 1.55M
MDXG Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MiMedx Group, Inc.NASDAQ: MDXG
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $4.14M rose 24.4% year over year, in line with the +24.0% change in trailing-twelve-month research & development. Sequentially, it fell 13.1% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.
Context
- Research & development amounted to 3.6% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24.4% holds above the trailing-twelve-month pace of +24.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 15.1M USD
- Year-over-year change
- +22.3%
- 4-year CAGR
- +11.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.1M | +22.3% |
| FY2024 | 2024-12-31 | 12.34M | -2.6% |
| FY2023 | 2023-12-31 | 12.67M | -0.3% |
| FY2022 | 2022-12-31 | 12.7M | +27.9% |
| FY2021 | 2021-12-31 | 9.93M | — |
Research & Development vs competitors
How MDXG compares with its peers on the latest reported figures
- MDXG's LTM Mar 2026 research & development of $15.91M is the 5th highest of the 8 companies compared; the peer median is $16.62M.
- Its year-over-year change of +24.0% is the 3rd highest of 8, against a peer median of -1.7%.
- Research & development amounts to 4.1% of revenue for MDXG, versus a peer median of 42.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $49.06M | +2.0% | +3.9% | 9.6% | |
| LTM Mar 2026 | $20.18M | -5.9% | +14.6% | 27.9% | |
| LTM Mar 2026 | $18.85M | +49.9% | +8.2% | 127.5% | |
| LTM Mar 2026 | $16.62M | +61.4% | +12.0% | 114.8% | |
| LTM Mar 2026 | $15.91M | +24.0% | +5.9% | 4.1% | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| LTM Jun 2026 | $5.31M | -1.7% | +285.9% | — | |
| LTM Mar 2026 | $5.08M | -13.4% | +14.6% | 4.7% | |
| Peer median (excluding MDXG) | $16.62M | -1.7% | +12.0% | 42.2% | |
Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 242.02M | 267.84M | 321.48M | 348.88M | 418.63M |
| Cost of Revenue | 39.63M | 48.32M | 54.63M | 60.07M | 73.01M |
| Gross Profit | 202.39M | 219.53M | 266.84M | 288.81M | 345.62M |
| Gross Margin | 83.6% | 82.0% | 83.0% | 82.8% | 82.6% |
| Research & Development | 9.93M | 12.7M | 12.67M | 12.34M | 15.1M |
| Selling, General & Admin | 194.85M | 220.85M | 216.3M | 216.39M | 266.19M |
| Operating Expenses | 209.44M | 234.25M | 229.73M | 229.94M | 281.29M |
| Depreciation & Amortization | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M |
| EBITDA | (1.89M) | (10.69M) | 40.52M | 65.35M | 82.93M |
| EBITDA Margin | -0.8% | -4.0% | 12.6% | 18.7% | 19.8% |
| Operating Income | (7.05M) | (14.73M) | 37.12M | 58.87M | 63.89M |
| Operating Margin | -2.9% | -5.5% | 11.5% | 16.9% | 15.3% |
| Interest Income | 0 | 0 | 0 | 0 | 4.72M |
| Interest Expense | 4.98M | 5.02M | 6.46M | 1.01M | 1.78M |
| Other Income / Expenses | (5M) | (5.02M) | (6.48M) | (1.57M) | 2.38M |
| Income Before Tax | (12.05M) | (19.75M) | 30.63M | 57.29M | 66.26M |
| Pre-Tax Margin | -5.0% | -7.4% | 9.5% | 16.4% | 15.8% |
| Income Tax Expense | 247K | 206K | (36.81M) | 15.3M | 17.68M |
| Net Income | (12.3M) | (30.2M) | 67.44M | 42.42M | 48.58M |
| Net Margin | -5.1% | -11.3% | 21.0% | 12.2% | 11.6% |
| EPS (Basic) | (0.09) | (0.27) | 0.48 | 0.29 | 0.33 |
| EPS (Diluted) | (0.09) | (0.27) | 0.38 | 0.28 | 0.32 |
| Weighted Avg Shares | 110.35M | 112.91M | 116.5M | 146.98M | 147.79M |
| Weighted Avg Shares (Diluted) | 110.35M | 112.91M | 145.96M | 149.05M | 149.72M |
MiMedx Group, Inc.
NASDAQ:MDXG
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.